Sharing. Perfect communication.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R M Carr.
Explore the source record for details and available documents.
In a phase II study dibromodulcitol (DBD), an alpha-omega dibrominated hexitol, was used to treat 99 previously treated patients with colon, rectal, kidney, and other tumors. Six patients were ineligible and 10 patients were nonevaluable for response. Aside from thrombocytopenia toxicity was moderate. Twenty-three patients had platelet nadirs of less than 50,000/mm3 and there were three thrombocytopenic-associated drug deaths. One of 21 rectal and 1 of 13 kidney cancer patients entered a remission. All but seven patients had received previous treatment with one or more cytotoxic agents. Previously treated patients with colorectal and kidney cancer appear to be resistant to DBD.
In a 75-year-old man, agranulocytosis and septicemia developed after eight weeks of quinidine sulfate therapy. An IgG antibody requiring the presence of quinidine was shown by complement-dependent leukocytotoxicity and leukoagglutination reactions. The antibody did not cross-react with quinine and was active against WBCs obtained from normal subjects and from the patient himself.
Explore the source record for details and available documents.
Two cases of acute myeloblastic leukemia were observed in Hodgkin's disease patients two and five years following intensive radiation therapy. Sixteen additional cases of acute granulocytic leukemia occurring in radiation-treated Hodgkin's disease patients have been reported in the literature and are reviewed. It is suggested that the development of acute leukemia was related to irradiation in these patients, and that additional such cases could be expected with the use of intensive radiation and chemotherapy, a risk probably justified in view of the improved control of Hodgkin's disease achieved by these programs.